The Dime Podcast Por Bryan Fields & Kellan Finney arte de portada

The Dime

The Dime

De: Bryan Fields & Kellan Finney
Escúchala gratis

The $100+ billion cannabis industry is fueled by innovative strategies and visionary leaders. Each week, we explore the journeys of CEOs from publicly traded giants, world-renowned scientists, and underground legacy growers shaping the future of this transformative market. Bryan and Kellan uncover how these pioneers built their businesses, navigated failures and found success in this rapidly growing space. Join us to explore the lessons and insights driving the cannabis industry forward.© 2025 The Dime Ciencia Economía Gestión Gestión y Liderazgo Liderazgo Química
Episodios
  • Largest Medical Cannabis & Cancer Study Ever: Can These Findings Push Rescheduling? ft Ryan Castle

    Largest Medical Cannabis & Cancer Study Ever: Can These Findings Push Rescheduling? ft Ryan Castle
    Sep 25 2025
    If you were given some of the worst news in the world, wouldn’t you expect your doctors to use every tool available?What if one of those tools could save millions of lives—and the science is already here?The world’s largest medical cannabis and cancer study—10,000 papers, ranked in the top 5% globally—shows overwhelming evidence that cannabis has medical benefits. If fully embraced, its impact on patients and medicine could be transformative. As science continues to unfold, sometimes it takes skeptics to dive deep and uncover what’s truly there, even when powerful interests push back.This week we sit down with Ryan Castle, Research Director at Whole Health Oncology Institute, to discuss:Medical cannabis: efficacy, placebo, and why it matters less than you thinkHow this study is being used in rescheduling effortsHow vested interests fuel anti-cannabis researchChapters00:00 Introduction to Medical Cannabis Research03:06 Ryan Castle's Journey into Cannabis Research05:58 The Meta-Analysis Process Explained09:00 Understanding the Data and Its Implications11:54 Skepticism and the Shift in Perspective15:01 Consensus in Medical Cannabis Research18:04 Nuances in Cancer Treatment and Cannabis20:55 Biomarkers and Inflammatory Responses22:56 Exploring Cannabis and Cancer Outcomes29:37 Bridging the Gap: Patient-Reported Outcomes35:32 The Future of Medical Cannabis Research45:34 The Cancer Playbook: Empowering Patients SummaryIn this episode, Bryan Fields and Kellan Finney engage with Ryan Castle, Research Director at Whole Health Oncology Institute, to explore the evolving landscape of medical cannabis research. Ryan shares his journey from skepticism to advocacy, detailing the extensive meta-analysis he conducted on the efficacy of cannabis in treating various symptoms and conditions, particularly in oncology. The conversation delves into the challenges of measuring effectiveness, the importance of patient-reported outcomes, and the need for a shift in medical perspectives towards cannabis as a legitimate treatment option. Ryan emphasizes the potential impact of policy changes and the importance of transparency in research, while also discussing the Cancer Playbook initiative aimed at empowering patients with data-driven insights. TakeawaysRyan Castle initially set out to prove that cannabis doesn't work.His extensive research revealed that cannabis is effective for a wide range of conditions.The meta-analysis included over 10,000 studies and 800,000 data points.Cannabis showed efficacy not just for symptoms but also for cancer treatment.Patient-reported outcomes are crucial for understanding cannabis effectiveness.The study found that cannabis can help reduce opioid dependency.There is a significant need for a shift in medical perspectives on cannabis.Transparency in research is essential for building trust in findings.The health impact assessment could reveal the broader benefits of cannabis.The Cancer Playbook initiative aims to empower patients with data-driven insights.Guest Linkshttps://wholehealthoncologyinstitute.com/Our LinksBryan Fields on TwitterKellan Finney on TwitterThe Dime on TwitterExtraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights.At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.The Dime is a top 5% most shared global podcastThe Dime is a top 10 Cannabis Podcast The Dime has a New Website. Shhhh its not finished.🎥 YouTube: The Dime📸 Instagram: The Dimehttps://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Más Menos
    49 m
  • Strategy Truths & Lies, Mature Industries Already Know ft. Mitchell Osak

    Strategy Truths & Lies, Mature Industries Already Know ft. Mitchell Osak
    Sep 18 2025
    Cannabis is chaotic by design. Vertical integration forces operators to run six or seven businesses at once — then replicate that model across states with different regulations, all without economies of scale. It’s no wonder the industry feels messy.The bigger problem? Too many companies are chasing the wrong metrics and ignoring the lessons other industries already learned.This week we sit down with Mitchell Osak — a veteran strategist across pharma, CPG, financial services, and cannabis — to unpack the hard truths and strategy lessons MSOs can’t afford to miss.In this episode we cover:• The wrong metrics driving cannabis off course — and which ones Mitch would track instead• Why TAM slides are the biggest lie in cannabis strategy• Which playbooks cannabis should borrow from pharma, wine, and techSummary:In this episode, Bryan Fields and Kellan Finney engage with Mitch Osak, a seasoned consultant in the cannabis industry. They explore Mitch's journey into cannabis consulting, the importance of strategic planning, and the challenges of standardization in the market. The conversation delves into the differences between large operators and middle market firms, the significance of understanding metrics, and the need for innovation. Mitch emphasizes the importance of learning from other industries, the role of AI, and the necessity for scenario planning in navigating the evolving landscape of cannabis. The episode concludes with insights on the future of the industry and the importance of external consultation.Chapters00:00 Introduction to the Cannabis Industry and Its Challenges04:01 Strategic Planning in Cannabis: A Holistic Approach06:01 Bridging the Gap: Cultivators vs. Financial Stakeholders09:46 Market Dynamics: The Rise of Middle Market Firms12:08 The Importance of Strategic Focus in Cannabis14:01 Understanding Quality and Consumer Insights18:10 The Role of Data and Metrics in Cannabis Business22:12 Cost Management vs. Quality Improvement25:50 Learning from Other Industries: Wine, Fashion, and Tech30:11 Future Opportunities in the Global Cannabis Market31:56 Navigating Regulatory Challenges and International Expansion33:04 The Importance of External Perspectives in Business Strategy35:32 Understanding Market Dynamics and Total Addressable Market (TAM)36:24 Opportunities in Distressed Assets and Market Entry39:10 Evaluating Acquisition Strategies and Asset Valuation41:27 The Complexity of Due Diligence in Cannabis Investments44:37 Scenario Planning for Future Industry Changes47:10 The Role of AI in Strategic Decision-Making51:25 Data as the Foundation for AI Success53:01 Preparing for Industry Consolidation and Survival Strategies TakeawaysMitch Osak has extensive experience in consulting across various industries, including cannabis.Strategic planning in cannabis requires a holistic approach, considering multiple factors.There is a disconnect between cultivators and investors in the cannabis industry.Standardization in the cannabis market is essential for growth and consistency.Middle market firms are gaining market share from larger operators due to strategic focus.Quality improvement should take precedence over merely cutting costs.External consultation can provide valuable insights for cannabis companies.Data and metrics are crucial for making informed decisions in the cannabis industry.AI can be a powerful tool, but it requires quality data to be effective.The cannabis industry must learn from other sectors to navigate its challenges. Guest Linkshttps://www.linkedin.com/in/mitchellosak/https://mitchellosak.substack.com/https://x.com/MitchellOsak Our LinksBryan Fields on TwitterKellan Finney on TwitterThe Dime on TwitterExtraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights.At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.The Dime is a top 5% most shared global podcastThe Dime is a top 10 Cannabis Podcast The Dime has a New Website. Shhhh its not finished.🎥 YouTube: The Dime📸 Instagram: The Dimehttps://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Más Menos
    56 m
  • THC Is an Ingredient, Where Pharma, MSOs & Hemp Collide, ft. Zach Edge

    THC Is an Ingredient, Where Pharma, MSOs & Hemp Collide, ft. Zach Edge
    Sep 11 2025

    THC is an ingredient.
    Cannabinoids will be treated like standardized inputs across pharma, licensed cannabis, and hemp—and the future winners are hedging until there’s clarity.

    What got you here won’t get you there. The next phase needs a new playbook: ops tweaks aren’t enough; strategy has to change.

    Near term, expect Schedule III to unlock e-pharmacy distribution and centralized GMP manufacturing, while tobacco pushes device rules, alcohol shapes low-dose beverage norms, and hemp keeps expanding.

    This chaotic industry is about to get even crazier.

    This week we sit down with Zach Edge to discuss

    • THC as a molecule
    • Intersection of pharma, hemp, and licensed cannabis:
    • Schedule III breakdown: e-pharmacies, centralized GMP

    Chapters

    00:00 Introduction to Zach Edge and His Journey

    03:11 The Changing Landscape of THC Commercialization

    07:45 Hedge Strategies in Cannabis and Hemp

    14:28 Regulatory Challenges and Future Outlook

    20:02 The Role of Science in Cannabinoid Production

    36:11 Innovations in Cannabinoid Purification

    45:20 Final Thoughts and Future Questions

    Summary

    In this episode, Bryan Fields and Kellen Finney engage with Zach Edge, a seasoned expert in the cannabis and hemp industries. Zach shares his journey into the cannabis space, highlighting the evolution of THC commercialization and the impact of regulation on the industry. He discusses the importance of a hedge strategy for businesses operating in multiple verticals, the challenges posed by varying state regulations, and the role of science in cannabinoid production and purification. The conversation also touches on the future of the industry, including potential growth in the hemp sector and the need for regulatory clarity.

    Guest Links

    • https://www.linkedin.com/in/zach-edge/
    • https://www.zachedge.com/

    Our Links

    Bryan Fields on Twitter

    Kellan Finney on Twitter

    The Dime on Twitter

    Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights.

    At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.

    The Dime is a top 5% most shared global podcast

    The Dime is a top 10 Cannabis Podcast

    The Dime has a New Website. Shhhh its not finished.

    🎥 YouTube: The Dime

    📸 Instagram: The Dime

    https://www.newton-insights.com/


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Más Menos
    43 m
Todavía no hay opiniones